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OBJECTIVES: Greek authorities have proposed draft
pharmacoeconomic (PE) guidelines for reimbursement
submissions. Our objective is to compare these to guide-
line documents in the EU countries, Australia and Canada
in terms of purpose and methodology and identify poten-
tial implementation problems. METHODS: We reviewed
and compared the proposed guidelines along the follow-
ing criteria: purpose of PE analysis, responsibility and
conduct, type of analysis, comparator choice, perspective,
resource use and cost assessment, outcome measurement
and validation of results. Based on the above as well as
current Greek literature we assessed potential problems
in implementing the proposed guidelines. RESULTS: In
terms of comparison, pharmacoeconomic submissions in
Greece aim at reimbursement. PE studies can be con-
ducted either by the pharmaceutical industry, CROs or
academia. Cost-minimization analysis is sufﬁcient when
effectiveness of the alternatives is equal. Otherwise, cost
consequence analysis is mandatory followed by cost-
effectiveness, cost-beneﬁt or cost-utility analyses. Stan-
dard and least costly existing therapies are mandatory
comparators. The perspective of analysis is not clearly
stated. Cost outcomes should reﬂect detailed resource use
description. Effectiveness measures should be based on
RCTs or meta-analysis results. No explicit reference is
made of naturalistic studies. Modeling is accepted. QoL
outcomes are accepted. Discounting and sensitivity analy-
ses are obligatory. As a result of our comparative analy-
sis, the following issues should be investigated in the
transition phase. Applying monetary values is difﬁcult
given the absence of ofﬁcial price lists and concurrent use
of public and private providers. Epidemiological data and
databases regarding clinical practice are scant. Extensive
modeling assumptions are required to transfer interna-
tional clinical data to the Greek environment. Experience
with PE is rare among researchers and government.
CONCLUSIONS: Proposed guidelines are similar with
published ones, with minor country-speciﬁc differences.
The implementation problems identiﬁed require a transi-
tion phase to establish methodological grounds and gen-
erate experience.
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OBJECTIVE: The ESAC project is funded by the Euro-
pean Commission to collect reliable and comparable data
on antibiotic consumption in all European countries. The
aim of this study is to identify the reimbursement status
of antimicrobials in participating countries and to assess
its impact on the comparability of utilization data col-
lected in national databases. METHODS: A structured
questionnaire was sent to national representatives in all
participating EU and applicant countries and obtained
data were validated by comprehensive literature search.
We limited this pilot analysis to reimbursement rules for
uncomplicated acute infection in adult persons (econom-
ically active), as co-payment schemes often vary widely,
depending on health and social status of patient.
RESULTS: Thirty countries participated. Two axes of 
differentiation were discovered in the reimbursement
systems. Firstly, the axis of homogeneity: is the reim-
bursement rate ﬁxed and identical across and among
antibiotic classes or not? Secondly the axis of initial
private payment: is the reimbursement system without
limitations or does the reimbursement start only above a
ﬁxed threshold co-payment (prescription cap) or a thresh-
old co-payment for multiple prescriptions over a given
period? Homogeneity without threshold co-payment was
observed most frequently (n = 13). Homogeneity, with
threshold co-payment was observed in eight countries. In
the remaining nine countries reimbursement status differs
across antibiotic classes, without reimbursement limita-
tion in six countries, with threshold co-payment in three
countries. CONCLUSIONS: In many European coun-
tries, claims databases based on dispensed reimbursed
medication sufﬁce to record antibiotic usage in a valid
way, as all antibiotics are to some extent reimbursed. In
the other countries, where not all antibiotics are reim-
bursed and/or where reimbursement starts only above a
threshold co-payment, data from claims databases will
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